Patents by Inventor Jan Tebbe

Jan Tebbe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210252161
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: February 3, 2021
    Publication date: August 19, 2021
    Inventors: Hans-Georg LERCHEN, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Christoph MAHLERT, Anne-Sophie REBSTOCK, Simone GREVEN, Nils GRIEBENOW, Jan TEBBE, Oliver KENSCH
  • Publication number: 20210147504
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 20, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Damian BROCKSCHNIEDER, Jan TEBBE, Andreas WILMEN, Frank WUNDER
  • Publication number: 20210139555
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 13, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
  • Patent number: 10973923
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 13, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Christoph Mahlert, Anne-Sophie Rebstock, Simone Greven, Nils Griebenow, Jan Tebbe, Oliver Kensch
  • Publication number: 20210079056
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 18, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER
  • Publication number: 20210054353
    Abstract: Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.
    Type: Application
    Filed: March 19, 2019
    Publication date: February 25, 2021
    Inventors: Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Michael Biag GAMALINDA, Ashish GUPTA, Christian PITZLER, Florian RICHTER, Jan TEBBE, Christopher CHENG, Ryo TAKEUCHI, Caroline W. REISS
  • Publication number: 20200385720
    Abstract: Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 10, 2020
    Inventors: Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Ashish GUPTA, Jan TEBBE, Cindy SCHULENBURG, Christian PITZLER, Michael Biag GAMALINDA, Sabine JACH, Florian RICHTER, Anup ARUMUGHAN, Corinna SAALWÄCHTER
  • Publication number: 20200239905
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 30, 2020
    Applicant: BASF Agricultural Solutions Seed US LLC
    Inventors: Marc Linka, Fabien Poree, Bernd Laber, Gudrun Lange, Ernst Weber, Michael Strerath, Sandra Geske, Heike Balven-Ross, Nina Wobst, Wayne Coco, Nikolaus Pawlowski, Jan Tebbe, Christina Thies, Manuel Dubald
  • Patent number: 10597674
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 24, 2020
    Assignee: BASF Agricultural Solutions Seed, US LLC
    Inventors: Marc Linka, Fabien Poree, Bernd Laber, Gudrun Lange, Jan Tebbe, Wayne Coco, Michael Strerath, Ernst Weber, Nikolaus Pawlowski, Sandra Geske, Heike Balven-Ross, Nina Wobst, Christina Thies, Manuel Dubald
  • Publication number: 20200063155
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Application
    Filed: March 1, 2018
    Publication date: February 27, 2020
    Applicant: BASF Agricultural Solutions Seed US LLC
    Inventors: Marc Linka, Fabien Poree, Bernd Laber, Gudrun Lange, Christina Thies, Ernst Weber, Michael Strerath, Sandra Geske, Heike Balven-Ross, Nina Wobst, Wayne Coco, Nikolaus Pawlowski, Jan Tebbe, Manuel Dubald
  • Publication number: 20190262463
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: August 29, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg LERCHEN, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Christoph MAHLERT, Anne-Sophie REBSTOCK, Simone GREVEN, Nils GRIEBENOW, Jan TEBBE, Oliver KENSCH
  • Publication number: 20180208937
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Application
    Filed: September 8, 2016
    Publication date: July 26, 2018
    Inventors: Marc Linka, Fabien POREE, Bernd LABER, Gudrun LANGE, Jan TEBBE, Wayne COCO, Michael STRERATH, Ernst WEBER, Nikolaus PAWLOWSKI, Sandra GESKE, Heike BALVEN-ROSS, Nina WOBST, Christina THIES, Manuel DUBALD
  • Publication number: 20170158775
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa C4.4a polypeptide, which is over expressed in several tumors, e.g. lung, colorectal, pancreas, prostate, renal and breast cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: February 6, 2017
    Publication date: June 8, 2017
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Lars LINDEN, Yong-Jiang CAO, Gabriele LEDER, Beatrix STELTE-LUDWIG, Axel HARRENGA, Ricarda FINNERN, Frank DITTMER, Anke MAYER-BARTSCHMID, Juergen FRANZ, Simone GREVEN, Jörg WILLUDA, Jan TEBBE
  • Patent number: 9657111
    Abstract: Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: May 23, 2017
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan Zhao, Zhuozhi Wang, Ji-Yun Kim, Ying Zhu, Jan Tebbe
  • Patent number: 9534046
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: January 3, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Patent number: 9309324
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: April 12, 2016
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
  • Publication number: 20150329629
    Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
    Type: Application
    Filed: April 24, 2015
    Publication date: November 19, 2015
    Inventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
  • Publication number: 20150322164
    Abstract: Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.
    Type: Application
    Filed: November 27, 2013
    Publication date: November 12, 2015
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Xiao-Yan ZHAO, Zhuozhi WANG, Ji-Yun KIM, Ying ZHU, Jan TEBBE
  • Publication number: 20140322220
    Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 30, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
  • Patent number: RE47150
    Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: December 4, 2018
    Assignee: Bayer HealthCare LLC
    Inventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska-Goebel, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brückner, Susanne Steinig, Peter Scholz